Expanding the Medical Equipment Business with Consumables Sales as a Growth Driver

「As a result, consumables revenue in the medical equipment business increased 3.5% from the prior fiscal year.」

「As a result, sales of consumables in the medical equipment business increased 2.7% from the year-earlier level.」

「The core growth driver of the medical equipment business is consumables sales. In recent years, we have particularly promoted sales activities focused on the Kansai region. As customer acquisition gained a certain degree of visibility, we upgraded the Kobe Sales Office of consolidated subsidiary Kawanishi Co., Ltd. to the Kansai Branch from this fiscal year to strengthen our sales base. As a result, sales of consumables in the medical equipment business increased 7.6% from the year-earlier level.」

「As a result, sales of consumables in the medical equipment business increased 6.3% from the previous fiscal year.」

「As a result, sales of consumables in the medical equipment business increased 6.4% from the year-earlier level.」

「As a result, sales of consumables in the medical equipment business increased 6.6% from the year-earlier level.」

「As a result, consumables revenue in the medical equipment business increased 6.7% year on year.」

「Against this backdrop, we worked to expand sales activities and improve procurement by drawing on our direct-sales capabilities. As a result, consumables revenue in the medical equipment business increased 4.2% from the prior fiscal year.」

「Against this backdrop, we worked to expand sales activities and improve procurement by drawing on our direct-sales capabilities. As a result, consumables revenue in the medical equipment business increased 4.1% year on year.」

「Against this backdrop, we worked to expand sales activities and improve procurement by drawing on our direct-sales capabilities. As a result, consumables revenue in the medical equipment business increased 4.0% year on year.」

「Against this backdrop, efforts to expand sales activities and improve procurement, supported by the company’s direct-sales capabilities, resulted in consumables revenue in the medical equipment business increasing 6.8% year on year.」

「As a result, consumables revenue in the medical equipment business increased 4.9% from the prior fiscal year.」

「The number of surgical cases began to trend upward from around autumn 2021 as medical institutions progressed with role-sharing and cooperation systems, vaccination rates improved, and infection-control measures within medical institutions advanced. To support these developments at medical institutions, we worked to provide services by mobilizing the full strength of the Group. As a result, sales of consumables in the medical equipment business increased 3.8% from the year-earlier level.」

「As a result, sales of consumables in the medical equipment business increased 3.5% from the year-earlier level.」

「As infection-control measures at medical institutions progressed, the number of surgical cases gradually recovered, and sales of consumables in the medical equipment business increased 2.3% from the year-earlier level.」

「Total consumables revenue, the growth driver, was affected by the continued decline in surgical cases associated with the spread of COVID-19, but ultimately increased 0.2% from the prior fiscal year.」

「Sales of total consumables, a growth driver, fell 2.5% year on year as a result of the continued impact of fewer surgeries accompanying the spread of COVID-19, hereinafter "COVID-19."」

「Sales of consumables as a whole, the core growth driver, continued to be affected by the decline in surgical cases associated with the spread of COVID-19, falling 2.7% from the year-earlier level. The breakdown is as follows. Sales of surgical consumables fell as the number of surgical cases declined with the spread of COVID-19, with core surgical products down 6.0% and anesthesia products down 11.3% from the year-earlier level. However, demand for PPE-related products increased as a result of COVID-19 countermeasures, driving a 68% increase, while diabetes-related products, a focus area, rose 5.1%, and laboratory products, including PCR testing equipment, increased 2.7%. As a result, total surgical consumables sales declined only 1.0%.」

「Sales of consumables as a whole, the core growth driver, fell 5.1% from the year-earlier level due to the decline in surgical cases associated with the spread of COVID-19. However, diabetes-related products, a focus area, rose 5.6%, while gastrointestinal endoscopy-related products increased 3.0%, providing positive signs for future growth.」

「Consumables revenue, the growth driver, increased 1.0% from the prior fiscal year despite product shortages and a decline in the number of surgeries associated with the spread of COVID-19.」

「Total consumables revenue, the growth driver, increased 4.3% year on year, in line with the overall increase in surgical cases and steady progress in developing new regional markets.」

「Sales of consumables as a whole, the core growth driver, rose 4.4% from the year-earlier level, supported by the overall increase in surgical cases and steady share gains in newly developed regions. The breakdown is as follows. Sales of surgical consumables rose 4.7% from the year-earlier level, following steady growth in surgical products, up 4.9% from the previous fiscal year, and anesthesia products, up 4.0% from the year-earlier level. Sales of diabetes-related products, a focus area, also rose 10.3%, supporting performance. Sales of orthopedic consumables increased with the overall rise in cases. In particular, the steady progress of cases at facilities newly acquired in the previous fiscal year resulted in a 4.1% increase from the year-earlier level. Sales related to catheter ablation remained solid in cardiovascular consumables. New cardiac treatment devices such as TAVI, or transcatheter aortic valve replacement, continued to drive performance in cardiovascular consumables, resulting in a 4.1% increase in sales from the year-earlier level.」

「Sales of consumables as a whole, the core growth driver, expanded with the overall increase in surgical cases, rising 7.5% from the year-earlier level. The breakdown is as follows. Sales of surgical consumables rose 8.7% from the year-earlier level, supported by steady growth in surgical products, up 7.8%, and anesthesia products, up 11.0%. Sales of diabetes-related products, a focus area, also rose 16.3%, supporting performance. Sales of orthopedic consumables increased across the board as the number of cases grew. In particular, the steady progress of cases at facilities newly acquired in the previous fiscal year resulted in a 7.6% increase from the year-earlier level. Sales of cardiovascular consumables remained solid, supported by catheter ablation-related sales. New cardiac treatment devices such as TAVI, or transcatheter aortic valve replacement, have been driving performance in cardiovascular consumables, resulting in a 4.8% increase in sales from the year-earlier level.」

「While maintaining sales of consumables in the medical equipment business, the core growth driver, at 1.2% above the previous fiscal year and broadly in line with the prior year, we kept the increase in selling, general and administrative expenses to 0.4% year on year.」

「Cardiovascular consumables were most significantly affected by the latest reimbursement price revision, with sales remaining at 98.7% of the year-earlier level. Meanwhile, demand for catheter ablation products, a designated growth area, continued to increase steadily, with sales rising to 109.3% of the year-earlier level. Catheter ablation uses radiofrequency energy to ablate myocardial tissue that causes tachycardia, or an abnormally rapid heartbeat. Sales of TAVI-related products, an area of focus for some time, rose sharply to 138.5% of the year-earlier level. TAVI is a minimally invasive procedure for implanting an artificial heart valve in the heart, providing a positive indication for the future.」

「As a result of implementing various initiatives to address this market environment of medical cost containment, consumables sales reached 101.3% of the year-earlier level, exceeding the prior year by 1.3 percentage points.」

「The reimbursement price revision implemented in April this year was an event with a significant impact on sales of consumables as a whole, the core growth driver. We implemented various initiatives to address a market environment in which curbing medical expenses is a key priority, but consumables sales were 99.6% of the year-earlier level, down 0.4 percentage points. Sales of surgical consumables grew to 122.0% of the year-earlier level in Tottori Prefecture, designated as a new market development area, and to 103.2% in Kagawa Prefecture following the acquisition of new SPD business.」

「Total revenue from consumables, the growth driver, remained solid, reaching 104.9% of the previous fiscal year's level.」

「Total revenue from consumables, the growth driver, remained solid despite a market environment of healthcare cost containment led by government policy, reaching 105.2% of the prior-year level. The breakdown is as follows. Surgical consumables continued to gain market share through new customer development in Kochi and Tottori prefectures. Market share also increased overall due to a rise in surgical procedures among existing customers in established regions and higher sales in the diabetes field. As a result, total revenue from surgical consumables reached 106.4% of the prior-year level. Orthopaedic consumables continued to generate higher sales through new customer acquisition, mainly in Kansai, increases in joint and trauma surgery cases across all areas, and higher average surgical prices in spinal surgery. As a result, total revenue from orthopaedic consumables reached 108.8% of the prior-year level. Prices for cardiovascular consumables used in cardiac vascular treatment continued to trend downward, but market-share expansion continued through support for the introduction of new products and technologies, mainly among major cardiovascular medicine customers. Demand for catheter-ablation products, which ablate the myocardial tissue causing tachycardia with radiofrequency energy, continued to expand, reaching 115.0% of the prior-year level, partly due to the impact of new products launched in the first quarter. In addition, strengthened sales activities targeting cardiovascular surgery opened up a new growth area. As a result, total revenue from cardiovascular consumables reached 103.8% of the prior-year level.」

「Total revenue from consumables, the growth driver, remained solid despite the challenging market environment of government-led healthcare cost containment, reaching 106.7% of the prior-year level. The breakdown is as follows. Surgical consumables continued to gain market share through steady new customer development in Kochi and Tottori prefectures. The number of surgical procedures, particularly endoscopic procedures, also increased among existing customers in established regions. As a result, total revenue from surgical consumables reached 108.4% of the prior-year level. Orthopaedic consumables generated higher sales through new customer acquisition, mainly in Kansai, and an increase in surgical cases. Cases also increased in the Chugoku and Shikoku regions, bringing total revenue from orthopaedic consumables to 111.0% of the prior-year level. Prices for cardiovascular consumables used in cardiac vascular treatment continued to trend downward, but market share expanded steadily through support for the introduction of new products and technologies, mainly among major cardiovascular medicine customers. Demand for catheter-ablation products, which ablate the myocardial tissue causing tachycardia with radiofrequency energy, continued to expand, reaching 115.2% of the prior-year level, partly due to the impact of new products launched in the first quarter. As a result, total revenue from cardiovascular consumables reached 110.2% of the prior-year level.」

「Total revenue from consumables, the growth driver, remained solid despite challenging market conditions, reaching 105.3% of the prior-year level. The breakdown is as follows. Surgical consumables increased market share in Kochi and Tottori prefectures through new customer development. Market share also increased overall, partly because expanded insurance coverage for certain products boosted sales. As a result, total revenue from surgical consumables reached 105.7% of the prior-year level. Orthopaedic consumables generated higher sales through new customer acquisition, mainly in the Kansai region, and an increase in surgical cases. New customer acquisition also progressed steadily in Shikoku, bringing total revenue from orthopaedic consumables to 109.4% of the prior-year level. Cardiovascular consumables were affected by falling prices for consumables used in cardiac vascular treatment and lower unit sales of cardiac pacemakers and other products. Demand for catheter-ablation products, however, continued to expand steadily, partly reflecting the launch of new products. New customer development in Shikoku also succeeded, bringing total revenue from cardiovascular consumables to 101.9% of the prior-year level.」

「Total consumables revenue reached 102.9% of the previous fiscal year's level. Revenue from surgical consumables reached 103.9%, orthopaedic consumables 104.4%, and cardiovascular consumables grew steadily, with catheter-ablation products reaching 121.4% of the previous fiscal year's level.」

「Total revenue from consumables, the growth driver, remained solid despite challenging market conditions, reaching 102.1% of the prior-year level. Sales of surgical consumables progressed, including surgical haemostatic agents, materials related to negative-pressure wound therapy and diabetes-related equipment such as blood glucose meters. New customer development progressed in areas with low market share, including Tokyo, Tochigi, Tottori, Kochi and Tokushima prefectures, delivering double-digit growth. Sales of orthopaedic consumables expanded steadily as new customer development progressed and cases increased among existing customers. In cardiovascular consumables, sales of catheter-ablation products grew to 122.8% of the prior-year level and are becoming a new growth driver for cardiovascular consumables.」

「Total revenue from consumables, the growth driver, remained solid despite challenging market conditions, reaching 103.2% of the prior-year level. Sales of surgical consumables progressed, including surgical haemostatic agents and diabetes-related equipment such as blood glucose meters, while new customer development in Tokyo, Tottori, Kochi and Tokushima prefectures delivered double-digit growth. Sales of orthopaedic consumables expanded as cases increased among existing customers and new customer development progressed steadily.」

「Total revenue from consumables, the growth driver, remained solid despite challenging market conditions, reaching 103.7% of the prior-year level. Sales rights for surgical consumables were acquired steadily, and market share increased in Tokyo, Hiroshima, Miyagi, Tottori and Kochi prefectures. Sales of orthopaedic consumables expanded, particularly for artificial joints, in the Kansai region, reflecting customers acquired in the previous fiscal year and the acquisition of a major facility during the current fiscal year.」

「Sales of consumables, the core driver of growth, continued to grow steadily, enabling us to secure sales revenue above the previous fiscal year.」